Organon will be responsible for the marketing, sales, and managed markets activities including pricing and contracting as well as recording sales for Anzemet Injection. The company will promote the injection to the anesthesia community within the hospital market.
Anzemet Injection is indicated for the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including high dose cisplatin.
“Organon is very excited about our agreement with Sanofi-Aventis for Anzemet for PONV (postoperative nausea and/or vomiting). We have a well-established commitment in anesthesia and we have maintained a leadership position with Zemuron for injection. Anzemet Injection will be a valued addition to our anesthesia portfolio,” said Michael Novinski, president of Organon USA.